Mineralys Therapeutics, Inc. (MLYS) Misses Q2 EPS by 11c
Tweet
Share
E-mailGet Alerts MLYS Hot Sheet
Join SI Premium – FREE
Mineralys Therapeutics, Inc. (NASDAQ: MLYS) reported Q2 EPS of ($0.83), $0.11 worse than the analyst estimate of ($0.72).
For earnings history and earnings-related data on Mineralys Therapeutics, Inc. (MLYS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Downgrades China Power International (2380:HK) (CPWIF) to Hold
- BofA says CTA Treasury shorts stable, euro short-cover risk rises
- HSBC Downgrades Kakao Corp. (035720:KS) to Hold
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
